Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Insight Molecular Diagnostics Inc.OCX · Entity 6631 | Director | June 23, 2023 | June 27, 2023 |
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | Director · Chairman | July 01, 2023 | July 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Insight Molecular Diagnostics Inc.
Report date June 23, 2023 · Filed June 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | Direct | 489,111 |
Reported balance
After 2023-06-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-23 · Grant · Acquired 20,000 · Balance 489,111 F1: The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.20 · Expires 2033-06-23 | Direct | 90,000 |
Reported balance
After 2023-06-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-23 · Grant · Acquired 90,000 · Balance 90,000 F4: Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. |
| Common Stock, no par valueSEC Table I · non-derivative | IndirectSee Footnote | 75,345 |
Reported balance
Holding disclosure · report date 2023-06-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 75,345 F2: The shares of common stock are held by Greenbelt Corp. The Reporting Person is the President of Greenbelt Corp. and in such capacity has the right to vote and dispose of the securities held by such entity. |
| Common Stock, no par valueSEC Table I · non-derivative | IndirectSee Footnote | 18,767 |
Reported balance
Holding disclosure · report date 2023-06-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 18,767 F3: The shares of common stock are held by Greenway Partners, LP. The Reporting Person is the General Partner of Greenway Partners, LP and in such capacity has the right to vote and dispose of the securities held by such entity. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.
F2: The shares of common stock are held by Greenbelt Corp. The Reporting Person is the President of Greenbelt Corp. and in such capacity has the right to vote and dispose of the securities held by such entity.
F3: The shares of common stock are held by Greenway Partners, LP. The Reporting Person is the General Partner of Greenway Partners, LP and in such capacity has the right to vote and dispose of the securities held by such entity.
F4: Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.
Lineage Cell Therapeutics, Inc.
Report date July 01, 2023 · Filed July 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.41 · Expires 2033-07-01 | Direct | 50,000 |
Reported balance
After 2023-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-01 · Grant · Acquired 50,000 · Balance 50,000 F1: Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2023 Filed Jul 3, 2023 21:46 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001493152-23-023346 · ownership.xml · derivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director · Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2033-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 21:30 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 90,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001493152-23-022667 · ownership.xml · derivative · entry 4 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-06-23 F4 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 21:30 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantCommon Stock, no par value | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-022667 · ownership.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 489,111 F1 · security: The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:13 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 30,000 | $0.21 | $6,447.00 |
DisclosureSEC source: 0001493152-23-021531 · ownership.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,111 Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 18:47 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 25,000 | $0.29 | $7,125.00 |
DisclosureSEC source: 0001493152-22-036605 · ownership.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,111 Read SEC document |
| December 01, 2022 Filed Feb 14, 2023 21:16 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GiftCommon Shares, no par value | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-004902 · ownership.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,430,545 F1 · price: Represents a gift of 25,000 common shares. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:20 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001493152-22-023383 · ownership.xml · derivative · entry 6 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-08-15 F4 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:20 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 5,000 | $0.97 | $4,850.00 |
DisclosureSEC source: 0001493152-22-023383 · ownership.xml · nonDerivative · entry 3 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,111 Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:20 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 5,000 | $0.97 | $4,850.00 |
DisclosureSEC source: 0001493152-22-023383 · ownership.xml · nonDerivative · entry 2 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,111 Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:20 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantCommon Stock, no par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-023383 · ownership.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,111 F1 · security: The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001493152-22-018681 · ownership.xml · derivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2032-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer. Read SEC document |
| June 24, 2022 Filed Jul 19, 2022 16:05 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-019820 · ownership.xml · derivative · entry 2 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Stock Units vested on June 24, 2022. F1 · derivative.expiration_date: The Restricted Stock Units vested on June 24, 2022. Read SEC document |
| June 24, 2022 Filed Jul 19, 2022 16:05 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionCommon Stock, no par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-019820 · ownership.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2021 Filed Feb 11, 2022 21:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GiftCommon Shares, no par value | 14,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-004013 · ownership.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,455,545 F1 · price: During December 2021, Mr. Kingsley gifted a total of 14,700 common shares. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 22:21 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001493152-21-015884 · ownership.xml · derivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Shares · 80,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2022, subject to the reporting person's continuous service with the issuer. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 20:32 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-015448 · ownership.xml · derivative · entry 2 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2022-06-24 F2 · derivative.exercise_date: The Restricted Stock Units shall vest one year from the date of grant, subject to the director's continued service as a director of the Company from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 20:32 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001493152-21-015448 · ownership.xml · derivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-06-23 F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company from the date of grant until the vesting date or,if earlier, until the next annual meeting of shareholders. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 17:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionStock Option (right to buy) · Derivative | 61,800 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001493152-21-015072 · ownership.xml · derivative · entry 4 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 61,800 shares Expires 2021-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option became exercisable in four equal quarterly installments after the date of grant on July 1, 2016. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 17:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 61,800 | $2.20 | $135,960.00 |
DisclosureSEC source: 0001493152-21-015072 · ownership.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,470,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2020 Filed Dec 28, 2020 21:46 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionOption to purchase common stock · Derivative | 65,271 | $1.34 Strike: $1.34 | $87,463.14 |
DisclosureSEC source: 0001493152-20-024410 · ownership.xml · derivative · entry 7 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,271 shares Expires 2020-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vested and became exercisable in equal quarterly installments on the last day of each calendar quarter over a four-year period from the date of grant on December 29, 2010. Read SEC document |
| December 28, 2020 Filed Dec 28, 2020 21:46 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionCommon Stock, no par value | 65,271 | $1.34 | $87,463.14 |
DisclosureSEC source: 0001493152-20-024410 · ownership.xml · nonDerivative · entry 3 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 21:46 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionOption to purchase common stock · Derivative | 1,237 | $1.34 Strike: $1.34 | $1,657.58 |
DisclosureSEC source: 0001493152-20-024410 · ownership.xml · derivative · entry 6 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,271 Underlying: Common Stock · 1,237 shares Expires 2020-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vested and became exercisable in equal quarterly installments on the last day of each calendar quarter over a four-year period from the date of grant on December 29, 2010. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 21:46 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | SaleCommon Stock, no par value | 900 | $2.55 | $2,295.00 |
DisclosureSEC source: 0001493152-20-024410 · ownership.xml · nonDerivative · entry 2 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,840 Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 21:46 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionCommon Stock, no par value | 1,237 | $1.34 | $1,657.58 |
DisclosureSEC source: 0001493152-20-024410 · ownership.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:12 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionOption to purchase common stock · Derivative | 10,516 | $1.34 Strike: $1.34 | $14,091.44 |
DisclosureSEC source: 0001493152-20-024283 · ownership.xml · derivative · entry 9 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,508 Underlying: Common Stock · 10,516 shares Expires 2020-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options vested and became exercisable in equal quarterly installments on the last day of each calendar quarter over a four-year period from the date of grant on December 29, 2010. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:12 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | SaleCommon Stock, no par value | 7,652 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-024283 · ownership.xml · nonDerivative · entry 5 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,503 F2 · price: Shares sold at price ranging from $2.54 - $2.55. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:12 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionCommon Stock, no par value | 10,516 | $1.34 | $14,091.44 |
DisclosureSEC source: 0001493152-20-024283 · ownership.xml · nonDerivative · entry 4 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:12 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionOption to purchase common stock · Derivative | 47,976 | $1.34 Strike: $1.34 | $64,287.84 |
DisclosureSEC source: 0001493152-20-024283 · ownership.xml · derivative · entry 8 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,024 Underlying: Common Stock · 47,976 shares Expires 2020-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options vested and became exercisable in equal quarterly installments on the last day of each calendar quarter over a four-year period from the date of grant on December 29, 2010. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:12 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | SaleCommon Stock, no par value | 5,148 | $2.54 | $13,075.92 |
DisclosureSEC source: 0001493152-20-024283 · ownership.xml · nonDerivative · entry 3 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,639 Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:12 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | SaleCommon Stock, no par value | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-024283 · ownership.xml · nonDerivative · entry 2 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,787 F1 · price: Shares sold at price ranging from $2.50 - $2.54. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:12 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionCommon Stock, no par value | 47,976 | $1.34 | $64,287.84 |
DisclosureSEC source: 0001493152-20-024283 · ownership.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 06:15 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantCommon Stock | 5,909 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-023586 · ownership.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,811 F1 · price: The shares of the Issuer's common stock were issued to the Reporting Person for the repayment of deferred compensation in lieu of cash at a price of $2.07 per share. Read SEC document |
| December 01, 2020 Filed Feb 12, 2021 22:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GiftCommon Shares, no par value | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-003685 · ownership.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,408,445 F1 · date: During December 2020, Mr. Kingsley gifted a total of 17,500 common shares. F1 · price: During December 2020, Mr. Kingsley gifted a total of 17,500 common shares. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001493152-20-012529 · ownership.xml · derivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Shares · 70,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: Will become exercisable on July 1, 2021, based upon continued service on the board of directors. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 17:34 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to purchase common stock · Derivative | 57,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001493152-20-011541 · ownership.xml · derivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires not disclosed F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. F1 · derivative.expiration_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| September 01, 2019 Filed Feb 14, 2020 21:45 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GiftCommon Shares, no par value | 32,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-002547 · ownership.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,425,945 F1 · date: During September 2019, Mr. Kingsley gifted a total of 32,000 common shares. F1 · price: During September 2019, Mr. Kingsley gifted a total of 32,000 common shares. Read SEC document |
| July 17, 2019 Filed Jul 19, 2019 20:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-19-042845 · doc4.xml · derivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-07-16 F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| July 01, 2019 Filed Jul 4, 2019 01:15 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001209191-19-041308 · doc4.xml · derivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Shares · 70,000 shares Expires 2029-06-30 F1 · derivative.exercise_date: Will become exercisable on June 30, 2020, based upon continued service on the board of directors. Read SEC document |
| March 08, 2019 Filed Apr 5, 2019 23:10 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantCommon Shares, no par value | 6,390 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-023894 · doc4.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,457,945 F1 · kind: Acquired pursuant to that certain Agreement and Plan of Merger, dated November 7, 2018 (the "Merger Agreement"), by and between the Issuer, Patrick Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Asterias Biotherapeutics, Inc., a Delaware corporation ("Asterias"). Pursuant to the Merger Agreement, each share of Series A common stock of Asterias was converted into the right to receive 0.71 common shares of the Issuer. F1 · shares: Acquired pursuant to that certain Agreement and Plan of Merger, dated November 7, 2018 (the "Merger Agreement"), by and between the Issuer, Patrick Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Asterias Biotherapeutics, Inc., a Delaware corporation ("Asterias"). Pursuant to the Merger Agreement, each share of Series A common stock of Asterias was converted into the right to receive 0.71 common shares of the Issuer. F1 · price: Acquired pursuant to that certain Agreement and Plan of Merger, dated November 7, 2018 (the "Merger Agreement"), by and between the Issuer, Patrick Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Asterias Biotherapeutics, Inc., a Delaware corporation ("Asterias"). Pursuant to the Merger Agreement, each share of Series A common stock of Asterias was converted into the right to receive 0.71 common shares of the Issuer. F2 · balance_after: Does not include shares that Mr. Kingsley may acquire through the exercise of certain options. Read SEC document |
| November 01, 2018 Filed Feb 15, 2019 01:47 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GiftCommon Shares, no par value | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-010466 · doc5.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,451,555 F1 · date: During November 2018, Mr. Kingsley gifted a total of 20,000 common shares. F1 · price: During November 2018, Mr. Kingsley gifted a total of 20,000 common shares. F2 · balance_after: Does not include shares that Mr. Kingsley may acquire through the exercise of certain options. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 21:51 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001209191-18-049416 · doc4.xml · derivative · entry 4 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-08-29 F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 22:47 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 70,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001209191-18-041312 · doc4.xml · derivative · entry 4 KINGSLEY ALFRED D · CIK 0001229339 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Shares · 70,000 shares Expires 2023-06-30 F2 · derivative.exercise_date: Will become exercisable on June 30, 2019, based upon continued service on the board of directors. Read SEC document |
| December 01, 2017 Filed Feb 15, 2018 02:48 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GiftCommon Shares, no par value | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-010227 · doc5.xml · nonDerivative · entry 2 KINGSLEY ALFRED D · CIK 0001229339 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By Greenbelt Corp. Disclosed balance after: 1,043,346 F3 · date: During December 2017, Greenbelt Corp. gifted a total of 100,000 common shares to certain charitable organizations. F3 · price: During December 2017, Greenbelt Corp. gifted a total of 100,000 common shares to certain charitable organizations. Read SEC document |
| October 01, 2017 Filed Feb 15, 2018 02:48 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GiftCommon Shares, no par value | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-010227 · doc5.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,471,555 F1 · date: During October 2017, Mr. Kingsley gifted a total of 10,000 common shares. F1 · price: During October 2017, Mr. Kingsley gifted a total of 10,000 common shares. F2 · balance_after: Does not include shares that Mr. Kingsley may acquire through the exercise of certain options. Read SEC document |
| August 17, 2017 Filed Aug 22, 2017 01:21 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Disposition to issuerCommon Shares, no par value | 300,000 | $2.81 | $843,000.00 |
DisclosureSEC source: 0001209191-17-049764 · doc4.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,481,555 F1 · shares: On August 17, 2017, Mr. Kingsley exchanged 300,000 BioTime common shares for 421,500 common shares of AgeX Therapeutics, Inc., a subsidiary of BioTime. F2 · balance_after: Does not include shares that Mr. Kingsley may acquire through the exercise of certain options. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 22:27 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | SaleCommon Shares, no par value | 150,000 | $2.80 | $420,000.00 |
DisclosureSEC source: 0001209191-17-047197 · doc4.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,781,555 F1 · shares: The securities were sold in a private transaction. Substantially all of the sale proceeds were invested in AgeX Therapeutics, Inc., a new subsidiary of BioTime. F2 · balance_after: Does not include shares that Mr. Kingsley may acquire through the exercise of certain options. Read SEC document |
| July 01, 2017 Filed Jul 6, 2017 00:34 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 50,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-17-043821 · doc4.xml · derivative · entry 4 KINGSLEY ALFRED D · CIK 0001229339 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2022-06-30 F2 · derivative.exercise_date: Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001209191-17-040980 · doc4.xml · derivative · entry 5 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-14 F2 · derivative.exercise_date: Will become exercisable in four equal installments on September 30, 2017, December 31, 2017, March 31, 2018, and one day before the Company's next annual meeting of shareholders, based upon continued service on the board of directors from the date of grant on June 15, 2017. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:23 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 16,300 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001209191-17-040980 · doc4.xml · derivative · entry 4 KINGSLEY ALFRED D · CIK 0001229339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 Underlying: Common Stock · 16,300 shares Expires 2027-06-14 F1 · shares: Options are granted to directors annually. These options are a "transitional grant" reflecting the change in the date of the annual grant from February to the date of the annual meeting of shareholders. The options are 32.60% of the annual grant for the 119-day gap between February 16, 2017, one year from the last annual grant, and June 15, 2017, date of the full annual grant for 2017-2018. F2 · derivative.exercise_date: Will become exercisable in four equal installments on September 30, 2017, December 31, 2017, March 31, 2018, and one day before the Company's next annual meeting of shareholders, based upon continued service on the board of directors from the date of grant on June 15, 2017. Read SEC document |
| January 03, 2017 Filed Jan 7, 2017 02:56 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | OtherCommon Shares, no par value | 238,469 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-002818 · doc4.xml · nonDerivative · entry 1 KINGSLEY ALFRED D · CIK 0001229339 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By Greenbelt Corp. Disclosed balance after: 1,143,346 F1 · date: Distribution to a shareholder in partial redemption of their shares of Greenbelt Corp. None of Mr. Kingsley's shares in Greenbelt Corp. have been redeemed. F1 · price: Distribution to a shareholder in partial redemption of their shares of Greenbelt Corp. None of Mr. Kingsley's shares in Greenbelt Corp. have been redeemed. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.